|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Avanir_Pharmaceuticals
gptkb:Astex_Pharmaceuticals
|
|
gptkbp:CEO
|
gptkb:Taro_Iwamoto
|
|
gptkbp:clinicalTrials
|
Conducts numerous clinical trials globally
|
|
gptkbp:employees
|
approximately 47,000
|
|
gptkbp:founded
|
1964
|
|
gptkbp:founder
|
gptkb:Akihiko_Otsuka
|
|
gptkbp:globalPresence
|
Operations in over 20 countries
|
|
gptkbp:headquarters
|
gptkb:Tokyo,_Japan
gptkb:Minato,_Tokyo
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Otsuka Pharmaceutical
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:market
|
Approximately $20 billion (2021)
|
|
gptkbp:notableFeature
|
gptkb:Samsca
gptkb:Vivitrol
gptkb:Rexulti
Abilify
Seroquel
|
|
gptkbp:parentCompany
|
gptkb:Otsuka_Holdings_Co.,_Ltd.
|
|
gptkbp:partnerships
|
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb
gptkb:Helsinn_Healthcare
gptkb:Mitsubishi_Tanabe_Pharma
|
|
gptkbp:philanthropy
|
gptkb:Otsuka_Foundation
Disaster relief efforts
Community health programs
Support for mental health initiatives
Support for education and research
|
|
gptkbp:products
|
Medical devices
Prescription drugs
Nutraceuticals
|
|
gptkbp:regulatoryCompliance
|
EMA_approved_drugs
FDA_approved_drugs
|
|
gptkbp:researchFocus
|
Oncology
Cardiovascular diseases
Infectious diseases
Central nervous system disorders
|
|
gptkbp:revenue
|
$11.5 billion (2020)
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stockSymbol
|
4578
|
|
gptkbp:subsidiary
|
gptkb:Otsuka_Pharmaceutical_Co.,_Ltd.
gptkb:Otsuka_America_Pharmaceutical,_Inc.
|
|
gptkbp:sustainabilityInitiatives
|
Sustainable sourcing practices
Environmental sustainability programs
Employee volunteer programs
Waste reduction initiatives
Corporate social responsibility programs
|
|
gptkbp:website
|
www.otsuka.com
|